Compare YELP & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YELP | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2011 | N/A |
| Metric | YELP | EVO |
|---|---|---|
| Price | $25.79 | $2.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $29.17 | $7.00 |
| AVG Volume (30 Days) | ★ 1.3M | 39.3K |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.15 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $1,464,955,000.00 | N/A |
| Revenue This Year | $2.19 | $1.37 |
| Revenue Next Year | $2.34 | $10.05 |
| P/E Ratio | $87.77 | ★ N/A |
| Revenue Growth | ★ 3.75 | N/A |
| 52 Week Low | $19.60 | $1.95 |
| 52 Week High | $35.26 | $4.42 |
| Indicator | YELP | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 25.09 |
| Support Level | $23.85 | N/A |
| Resistance Level | $27.23 | $3.36 |
| Average True Range (ATR) | 1.04 | 0.10 |
| MACD | 0.02 | -0.08 |
| Stochastic Oscillator | 40.66 | 5.10 |
Yelp Inc operates in the online content market based in the United States. It provides a web-based platform and mobile application to bridge the gap between businesses and consumers. The platform assists consumers through product reviews, tips, photos and videos thereby enabling them in making appropriate buying decisions and posting their feedbacks. Its products and services includes Advertising Products and Business Page Products. In addition, it also lets the buyers directly transact with businesses directly through its platform. Yelp generates revenue mainly from the sale of advertising on its website and mobile app to businesses. The company generates majority of the revenue from United States, and also has its presence in other countries.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.